dc.contributor.author |
Pandya, Yogi |
|
dc.contributor.author |
Patel, Samixa |
|
dc.date.accessioned |
2023-05-01T08:00:23Z |
|
dc.date.available |
2023-05-01T08:00:23Z |
|
dc.date.issued |
2022-05-01 |
|
dc.identifier.citation |
Pandya, Y., & Patel, S. (2022). RP-HPLC stability method development & validation for anti-HIV drugs cabotegravir & rilpivirine in I.M. injection and in human plasma. International Journal of Health Sciences, 6(S1), 9104–9117. https://doi.org/10.53730/ijhs.v6nS1.7056 |
en_US |
dc.identifier.issn |
9104–9117 |
|
dc.identifier.uri |
http://10.9.150.37:8080/dspace//handle/atmiyauni/836 |
|
dc.description.abstract |
In Pharmaceutical & Medical Health Sciences there are
necessities for development of analysis methods for medicines in
various dosage forms. Currently the use of RP-HPLC is primarily
applied for testing of medicines in various dosage forms, and to study
bio analysis in human plasma matrix. The present method is
developed for analysis of anti HIV drugs cabotegravir CAB and
rilpivirine RILP in pure api & Intramuscular Injection dosage forms,
and also in human plasma. The HPLC method is optimized for
analysis of these two drugs in combined forms for swift analysis with
very less amount of drugs utilized for testing purposes. The
concentration range used for the linearity studies is 2.5 to 15μg/ml
for CAB cabotegravir & for Rilpivirine RILP it is 3.75 to 22.5μg/ml.
Wavelength selected for estimation is 242.5nm and column used was
Kinetex C-18 column (250mm x 4.6mm, 5 μm id). The Retention-time
obtained were 2.14min for CAB & 3.12min for RILP. The R2 was found
to be 0.999 for both drugs. The method is applied for analysis of drugs
in i.m. injections, individually & in combined forms. The Stability &
forced-degradations studies were carried out in different stress
conditions and the impurities & pure drugs, are efficiently detected by
the developed HPLC method. |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
International Journal of Health Sciences |
en_US |
dc.subject |
RP-HPLC |
en_US |
dc.subject |
Stability |
en_US |
dc.subject |
Antiviral |
en_US |
dc.subject |
HIV |
en_US |
dc.subject |
Cabotegravir |
en_US |
dc.subject |
Rilpivirine |
en_US |
dc.subject |
I.M. Injection |
en_US |
dc.subject |
Human Plasma |
en_US |
dc.title |
RP-HPLC stability method development & validation for anti-HIV drugs cabotegravir & rilpivirine in I.M. injection and in human plasma |
en_US |
dc.type |
Article |
en_US |